Open AccessGLP ‐1 Receptor Agonists: Effects on Cardiovascular Risk Reduction
Author(s) -
Lorber Daniel
Publication year - 2013
Publication title -
cardiovascular therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.818
H-Index - 46
eISSN - 1755-5922
pISSN - 1755-5914
DOI - 10.1111/1755-5922.12000
Subject(s) - medicine , liraglutide , exenatide , dyslipidemia , weight loss , incretin , type 2 diabetes , glucagon like peptide 1 receptor , glycemic , endocrinology , diabetes mellitus , blood pressure , type 2 diabetes mellitus , obesity , pharmacology , agonist , receptor
Summary Comorbid obesity, dyslipidemia, and hypertension place patients with type 2 diabetes ( T 2 DM ) at greatly increased risk of cardiovascular ( CV ) disease‐related morbidity and mortality. An urgent need exists for effective treatment for patients with T 2 DM that encompasses glycemic control, weight loss, and reduction in CV risk factors. The glucagon‐like peptide‐1 receptor agonists ( GLP ‐1 RA s) liraglutide and exenatide are incretin‐based antidiabetes agents. This review examines CV ‐associated effects of liraglutide and exenatide in animal models and clinical trials with patients with T 2 DM . Studies support the effectiveness of GLP ‐1 RA s in reducing hyperglycemia. Further, GLP ‐1 RA s represent a significant advance in T 2 DM treatment because they uniquely affect a broad array of CV risk factors through significant weight and systolic blood pressure reduction, improved lipid levels, and possibly, as shown in in vitro studies and animal models, through direct effects on cardiac myocytes and endothelium.